STAQ Pharma, a 503B outsourcing supplier with facilities in Denver and Columbus, Ohio, is showing the power of collaboration between industry stakeholders through its approach to combating drug shortages in the vulnerable oncology market.
The company’s most recent effort, announced this past summer, was to safely produce two oncology drugs that have been on chronic shortage: cisplatin and methotrexate. STAQ appears to be the only 503B outsourcing supplier compounding such chemotherapy